11.12.2017 • NewsElaine BurridgeBYKadditives

BYK Expands Texas Additives Plant

(c) twitter.com/PressBYK/media
(c) twitter.com/PressBYK/media

US additives and instruments supplier BYK, which is part of German specialty chemicals group Altana, will invest $50 million to expand its facility in Gonzales, Texas.

BYK is to increase capacities and capabilities for key products in its portfolio, specifically Garamite, which is a range of natural rheology additives. The company explained that Garamite additives have a thickening effect and can replace alternative solutions, for example, in coatings where they can contribute to the lightweight construction of cars, a key trend in the automotive industry where manufacturers are working to cut carbon emissions.

The project includes several upgrades to the site’s infrastructure as well as a new R&D facility to house a global competence center for natural rheology.

BYK is also investing in China, where it broke ground in July on a new facility in the Shanghai Chemical Industry Park. The Connecticut-based company is spending more than $30 million on the complex, which will combine R&D, technical service, logistics and administrative functions under one roof, while also forming the basis for a continued expansion in Greater China and the whole Asia-Pacific region.

The facility is scheduled to go into operation in the second half of 2018.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.